Early detection reduces mortality in Cancer patients. Expression of microRNA-10b can be used as a diagnostic biomarker to detect the presence of metastasis as well as a biomarker to predict overall survival and disease-free survival in cancer.
TransCode Therapeutics has created a specific biomarker (companion) test that can quantify microRNA expression in patient serum or freshly biopsied tissue and is intended to be used to measure the response to therapy with TTX-MC138 (for microRNA-10b). This capability could be instrumental in determining which patients are likely to respond to therapy with TTX-MC138 and in measuring therapeutic response during and after treatment in TransCode’s PHII clinical trial.
TransCode’s microRNA nanosensor could address a major unmet need in the areas of cancer biology, diagnosis, and therapy by introducing a tool that could permit the analysis of microRNA expression in intact live cells and tissues. This unique capability is a transformative approach to cancer as the currently established methods are destructive to the cell and therefore do not permit longitudinal studies that assess response to therapy. TransCode’s microRNA nanosensor approach offers that possibility.
- TransCode’s predictive biomarker nanosensor has the unique capability of microRNA profiling in intact live cells and tissues.
- The fluorescent read-out generated by the nanosensor is highly specific and has nanomolar sensitivity.
- The nanosensor assay can be used to determine microRNA expression in biopsies, serum, and circulating tumor cells, developed for intraoperative and laparoscopic diagnostics, as well as intended for use in monitoring treatment response with TTX-MC138 in clinical trials.